Group 1 - The 17th China Pharmaceutical Entrepreneurs Scientists Investors Conference, themed "Structural Turning Point," was held from November 24 to 26, 2025, in Haidian District, Beijing [1] - The conference serves as a high-profile platform for value linkage in the Chinese pharmaceutical industry and is a key event of the "Intelligent Gathering Haidian" talent theme week [1] - The establishment of the "National Traditional Chinese Medicine Inheritance and Innovation Center" at Xiyuan Hospital was witnessed by national and municipal authorities during the conference [1] Group 2 - The Haidian District "Zhongguancun Science City Technology Growth Fund" has reached a total scale of 20 billion yuan across three phases, focusing on the pharmaceutical and health sectors [2] - The fund aims to expand its scale through collaboration with market-oriented investment institutions, creating a comprehensive investment matrix to support the entire pharmaceutical health industry chain [2] - Haidian District is committed to becoming an innovation hub and investment hotspot for the pharmaceutical health industry by integrating technological and industrial innovation [2]

Meeting Details - The 33rd meeting of the 9th Board of Directors of China National Pharmaceutical Group Co., Ltd. was held on November 24, 2025, in a combination of in-person and communication methods, chaired by Chairman and General Manager Yang Guang [2] - The meeting notification was sent to all directors on November 19, 2025, via email, SMS, phone, or fax [3] - A total of 8 directors were supposed to attend the meeting, and all 8 directors actually participated [4] - The meeting was conducted in accordance with the relevant provisions of the Company Law and the Articles of Association, making the resolutions valid [5] Resolutions Passed - The meeting approved the proposal to revise the "Internal Audit Work Regulations" [6] - The voting results for this proposal were unanimous, with 8 votes in favor, 0 against, and 0 abstentions [8] - The meeting also approved the proposal to establish the "Board Meeting Proposal Management Measures" [9] - The voting results for this proposal were also unanimous, with 8 votes in favor, 0 against, and 0 abstentions [11]

中国医药健康产业股份有限公司 董事会议案管理办法 第一章 总则 第一条 为规范中国医药健康产业股份有限公司（以下简 称"公司"）董事会议案管理，提高董事会规范运作水平和 议事效率，加强决策的科学性，根据《中华人民共和国公司 法》《中华人民共和国证券法》等法律法规、规范性文件和 《中国医药健康产业股份有限公司章程》（以下简称"《公 司章程》"）《中国医药健康产业股份有限董事会议事规则》 （以下简称"《董事会议事规则》"）等规定，制定本办法。 第二条 本办法所称董事会议案，是指根据《公司章程》 《董事会议事规则》等有关规定提交董事会审议事项的正式 文件材料。 第三条 董事会议案的提议人主体，可通过董事会办公室 提交具体议案及其附件材料。提议人主体包括： （一）董事长； 第二章 议案的主要内容 1 （二）代表十分之一以上表决权的股东； （三）三分之一以上董事； （四）审计与风控委员会； （五）二分之一以上独立董事； （六）总经理； （七）《公司章程》规定的其他情形。 第四条 提交董事会的议案应当属于董事会职权范围，具 体以《公司章程》和《董事会议事规则》等相关规定为准。 第五条 提交董事会的议案内容应做到目标明确， ...

内部审计工作规定 第一章 总 则 第一条 为加强和规范中国医药健康产业股份有限公司 （以下简称"公司"）内部审计工作，完善公司内部审计制 度，提升内部审计工作质量，促进公司依法合规经营，根据 《中华人民共和国审计法》及其《实施条例》《审计署关于 内部审计工作的规定》《上海证券交易所上市公司自律监管 指引第 1 号——规范运作》以及《中国医药健康产业股份有 限公司章程》等有关规定和要求，制定本规定。 第二条 公司内部审计工作坚持以习近平新时代中国特 色社会主义思想为指导，以习近平总书记关于审计工作重要 指示批示精神为根本遵循，坚决贯彻党中央"应审尽审、凡 审必严、严肃问责"的指导思想和构建"集中统一、全面覆 盖、权威高效"审计监督体系的总体要求，坚持公司党委对 内部审计工作的全面领导，立足新发展阶段，贯彻新发展理 念，构建新发展格局，以推动高质量发展为主题，紧密围绕 党中央重大决策部署和公司发展战略落实情况，全面履行审 计监督职责，拓展审计监督广度和深度，突出对重点单位、 重大资金和重要项目的审计监督，揭示经营管理中的重大风 险隐患，促进公司做强做优做大、实现高质量发展。 中国医药健康产业股份有限公司 第九条 ...

证券代码：600056 证券简称：中国医药 公告编号：临2025-088号 中国医药健康产业股份有限公司 第九届董事会第 33 次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、会议召开情况 中国医药健康产业股份有限公司董事会 (三)本次会议应参加会议董事8名，实际参加会议董事8名。 (四)本次会议的召开符合《公司法》及《公司章程》的有关规定，会议决议为 有效决议。 二、会议审议情况 本次会议审议并通过如下议案： （一）审议通过了《关于修订<内部审计工作规定>的议案》。 制度全文请详见上海证券交易所网站（www.sse.com.cn）。 表决结果：同意 8 票；反对 0 票；弃权 0 票。 （二）审议通过了《关于制定<董事会议案管理办法>的议案》。 制度全文请详见上海证券交易所网站（www.sse.com.cn）。 表决结果：同意 8 票；反对 0 票；弃权 0 票。 特此公告。 (一)中国医药健康产业股份有限公司(以下简称"公司")第九届董事会第33次 会议（以下简称"本次会议"）于2025年11月24日以 ...

Summary of Expert Call on China's Pharma Market Industry Overview - **Industry**: Pharmaceutical Industry in China - **Focus**: Multinational Corporations (MNCs) and their strategies in the Chinese market Key Insights 1. **Long-term Strategic Focus**: China is viewed as a top-five market for MNCs due to its large population and aging demographics, maintaining its strategic importance despite cost control policies impacting revenue growth [2][8][9] 2. **Cost Control Policies**: Policies like Value-Based Pricing (VBP) and Diagnosis-Related Groups (DRG) have led MNCs to shift focus from off-patent drugs to innovative drug sales, akin to a "patent cliff" scenario [3][8] 3. **Out-of-Pocket (OOP) Market**: MNCs are prioritizing the OOP market, which, despite higher prices compared to National Reimbursement Drug List (NRDL) drugs, has seen reduced patient costs through assistance programs and commercial insurance [3][10][11] 4. **In-Licensing Strategies**: MNCs are increasingly in-licensing innovative assets from China, driven by the improving quality of Chinese clinical trial data and faster development speeds [4][12][14] 5. **Collaboration Models**: New collaboration models are emerging, such as establishing NewCos and co-development agreements, as Chinese firms seek international R&D expertise [15][12] 6. **Regulatory Environment**: The Chinese pharmaceutical market is highly regulated, with ongoing refinements to policies like VBP, which now emphasizes drug quality [9][18] Additional Considerations 1. **Impact of CIDL**: The newly launched Commercial Insurance Innovative Drug List (CIDL) negotiations are expected to unlock growth opportunities for innovative drugs, particularly high-cost treatments [2][9] 2. **Geopolitical Factors**: MNCs are less focused on geopolitical factors when in-licensing Chinese assets, prioritizing therapeutic fit and strategic alignment instead [14] 3. **Quality of Clinical Trials**: MNCs maintain high standards for clinical trial data, with increasing investments in Chinese assets reflecting confidence in the quality of local clinical data [13][12] 4. **Risks in the Market**: Potential risks include unexpected price cuts from Group Purchasing Organizations (GPOs), intensified competition, and stricter regulations [18] This summary encapsulates the insights from the expert call regarding the evolving landscape of the pharmaceutical industry in China, highlighting both opportunities and challenges for MNCs operating in this market.

Policy Developments - The National Medical Products Administration (NMPA) has expanded the scope of export certificates for pharmaceuticals, allowing companies to apply for export certificates for drugs produced under GMP, regardless of whether they are approved for sale in China [2] - The validity period for the "Drug Export Sales Certificate" has been extended from 2 years to 3 years, aligning it with the "Export Certificate for EU Raw Materials" [2] - The maximum processing time for export certificates has been set at 20 working days, excluding the time required for technical reviews and on-site inspections [2] Drug and Device Approvals - Heng Rui Medicine has received clinical trial approval notices for multiple drugs, including SHR-9839 and SHR-A2009, and will soon commence clinical trials [4] - Renfu Medicine's application for the marketing authorization of Dexmethylphenidate Capsules has been accepted, targeting ADHD treatment, marking a significant step as no similar products are currently available in China [5] - Baile Tianheng's innovative EGFR×HER3 dual-target ADC drug, iza-bren, has had its marketing application accepted, being the first of its kind to enter Phase III clinical trials [6] Capital Markets - Eli Lilly has become the first healthcare company to reach a market capitalization of $1 trillion, with its stock price increasing by 38% this year, driven by investor optimism regarding its weight-loss drug [8] - Changshan Pharmaceutical's controlling shareholder plans to transfer 5% of its shares to Element Fund at a price of 46.25 yuan per share, totaling 2.1275 billion yuan [9][10] Industry Events - A medical representative was sentenced to eight months in prison for fraudulently altering gene test reports to defraud health insurance, highlighting the increasing scrutiny and regulatory measures in the pharmaceutical industry [12] - Heng Rui Medicine has signed a partnership agreement with the Hong Kong Greater China Cancer Foundation to provide innovative therapies for breast cancer patients in Hong Kong [13] - Baicheng Medicine has entered into an exclusive licensing agreement with Zhongshen Innovation for the innovative drug BIOS-0629 in the Greater China region, with milestone payments of 300 million yuan [14] Public Opinion Alerts - Li Xin, former member of the Party Committee and assistant general manager of China Pharmaceutical Health Industry Co., is under investigation for serious violations of discipline and law [16]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600056 证券简称：中国医药 公告编号：临2025-086号 中国医药健康产业股份有限公司 关于公司涉及诉讼事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示: ● 案件所处的诉讼阶段：二审 ● 上市公司所处的当事人地位：上诉人 ● 涉案的金额：13,940.41万元 公司已在法定期限内就北京市第二中级人民法院（"一审法院"）作出的（2024）京02民初1131号民事判 决书（"一审判决"）依法提起上诉，西藏天晟亦就一审判决提起上诉。 三、本次诉讼案件对公司的影响 截至本公告披露日，本次诉讼二审尚未开庭审理，最终审理结果存在不确定性。公司将根据上述诉讼事 项进展情况履行相关信息披露义务，敬请广大投资者注意投资风险。 特此公告。 中国医药健康产业股份有限公司董事会 2025年11月22日 证券代码：600056 证券简称：中国医药 公告编号：临2025-087号 ● 是否会对上市公司损益产生负面影响：截至本公告披露日，本次诉讼二审尚未开庭审 ...

Group 1: Shareholding Changes - Company Zhaoyi Innovation announced that several directors and senior management personnel plan to reduce their holdings by a total of 249,000 shares, with specific reductions from the vice chairman and general manager, as well as other vice presidents [1] - Company Super Aerospace announced a stock suspension due to its controlling shareholders planning a significant matter that may lead to a change in control [2] - Company Haosai is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws [5] Group 2: Major Contracts and Projects - Company Dajin Heavy Industry's wholly-owned subsidiary signed a contract worth approximately 1.339 billion yuan for a European offshore wind farm project, which represents 35.41% of the company's audited revenue for 2024 [3] - Company Ruifeng New Materials plans to increase capital by 200 million yuan in a related party to advance a lithium hexafluorophosphate project [6] Group 3: Regulatory Actions - Company Jushi Chemical received a notice from the CSRC regarding an investigation for suspected violations of information disclosure laws [4] - Company Huosai is also under investigation by the CSRC for similar reasons [5] Group 4: Investment and Acquisitions - Company Gao Neng Environment plans to acquire 45.2% equity in three mining companies [7] - Company Aerospace Electric intends to purchase 32% equity in Shenzhen Aerospace Electric Motor System Co., Ltd. through public bidding [8]

Core Points - China National Pharmaceutical Group Corporation (referred to as "China Pharmaceutical") disclosed a lawsuit update on November 22, involving a performance compensation contract dispute amounting to 139.4041 million yuan (approximately 1.39 billion yuan) [1] - The lawsuit originated from a performance compensation contract dispute that occurred in October 2024, with China Pharmaceutical as the plaintiff against Tibet Tiansheng Taifeng Pharmaceutical Co., Ltd. and Xu Panfeng [1] - The first-instance court has made a civil judgment, but both China Pharmaceutical and Tibet Tiansheng have appealed the decision, and the case is currently in the second-instance stage, awaiting trial [1] Summary by Sections Lawsuit Details - The lawsuit involves a total amount of 139.4041 million yuan, primarily concerning disputes over the performance compensation contract [1] - As of the announcement date, the second-instance trial has not yet commenced, and the final outcome remains uncertain [1] Company Actions - China Pharmaceutical has previously disclosed relevant information regarding the lawsuit through temporary announcements and regular reports on October 12, 2024, and October 11, 2025 [1]